These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 28633365)

  • 21. Copanlisib in the treatment of non-Hodgkin lymphoma.
    Narkhede M; Cheson BD
    Future Oncol; 2020 Sep; 16(26):1947-1955. PubMed ID: 32658557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.
    Fukuhara N; Maruyama D; Hatake K; Nagai H; Makita S; Kamezaki K; Uchida T; Kusumoto S; Kuroda J; Iriyama C; Yanada M; Tsukamoto N; Suehiro Y; Minami H; Garcia-Vargas J; Childs BH; Yasuda M; Masuda S; Tsujino T; Terao Y; Tobinai K
    Int J Hematol; 2023 Jan; 117(1):100-109. PubMed ID: 36175779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
    Yhim HY; Kim T; Kim SJ; Shin HJ; Koh Y; Kim JS; Park J; Park GS; Kim WS; Moon JH; Yang DH
    Ann Oncol; 2021 Apr; 32(4):552-559. PubMed ID: 33352201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
    Cheson BD; O'Brien S; Ewer MS; Goncalves MD; Farooki A; Lenz G; Yu A; Fisher RI; Zinzani PL; Dreyling M
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):135-141. PubMed ID: 30584024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
    Liu W; Ping L; Xie Y; Sun Y; Du T; Niu Y; Cisternas G; Huang F; Garcia-Vargas J; Childs BH; Mehra A; Reschke S; Wang X; Song Y; Zhu J
    Cancer Chemother Pharmacol; 2022 Jun; 89(6):825-831. PubMed ID: 35322287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
    Kim RD; Alberts SR; Peña C; Genvresse I; Ajavon-Hartmann A; Xia C; Kelly A; Grilley-Olson JE
    Br J Cancer; 2018 Feb; 118(4):462-470. PubMed ID: 29348486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
    Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
    N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma.
    Kumar A; Bhatia R; Chawla P; Anghore D; Saini V; Rawal RK
    Anticancer Agents Med Chem; 2020; 20(10):1158-1172. PubMed ID: 32183683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.
    Guo Z; Luo J; Mashl RJ; Hoog J; Maiti P; Fettig N; Davies SR; Aft R; Held JM; Govindan R; Ding L; Li S; von Morze C; Wulf GM; Shoghi KI; Ma CX
    Cancer Res Commun; 2024 Jun; 4(6):1430-1440. PubMed ID: 38717161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II Study of Copanlisib in Patients With Tumors With
    Damodaran S; Zhao F; Deming DA; Mitchell EP; Wright JJ; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Suga JM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    J Clin Oncol; 2022 May; 40(14):1552-1561. PubMed ID: 35133871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
    Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
    Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.
    Mensah FA; Blaize JP; Bryan LJ
    Onco Targets Ther; 2018; 11():4817-4827. PubMed ID: 30147333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
    Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
    Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
    J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
    Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
    Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
    Kim JH; Kim WS; Park C
    BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):14-6. PubMed ID: 24852792
    [No Abstract]   [Full Text] [Related]  

  • 39. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
    Flinn IW; Miller CB; Ardeshna KM; Tetreault S; Assouline SE; Mayer J; Merli M; Lunin SD; Pettitt AR; Nagy Z; Tournilhac O; Abou-Nassar KE; Crump M; Jacobsen ED; de Vos S; Kelly VM; Shi W; Steelman L; Le N; Weaver DT; Lustgarten S; Wagner-Johnston ND; Zinzani PL
    J Clin Oncol; 2019 Apr; 37(11):912-922. PubMed ID: 30742566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
    Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
    J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.